200 cologyVol35No.32020www.svzlzz.con [18] Kapitanovic S, Radosevic S, Kapitanovic M, et al. The ex cancer]. N Engl j Med,2005,353(16:1673-1684 pression of p185(HER-2/neu)correlates with the stage of [32] Clark J, Niedzwiecki D, Hollis D, et al. Phase-I trial of disease and survival in colorectal cancer[J].Gastroenter- 5-fluororuacil (5-FU), leucovorin(LV), oxaliplatin(Ox). ology,1997,112(4):1103-1113 and trastuzumab(n) for patients with metastatic colorectal [19] Osako T Miyahara M. Uchino S et al. Immunohistochem- cancer( CRC)refractory to initial therapy [J].Onkologie ical study of c-erbB-2 protein in colorectal cancer and 2003,26:13-46. the correlation with patient survival [J] Oncology, 1998, [33] Ramanathan RK, Hwang JJ, Zamboni WC, et al. Low 55(6:548-555 overexpression of HER-2/neu in advanced colorectal can [20] Laurent-Puig P. Balogoun R Cayre A. et al. ERBB2 al- cer limits the usefulness of trastuzumab(Herceptin)and terations a new prognostic biomarker in stage I colon irinotecan as therapy. A phase I trial[J]. Cancer Invest, cancer from a FolFoX based adjuvant trial(PETACC8) 2004,22(6:858-865 [J. Ann oncol,2016,27(supl6):149-206 [34] La Salvia A, Lopez-Gomez V, Garcia-Carbonero R [21] Kountourakis P, Pavlakis K, Psyrri A, et al. Clinicopath- HER2-targeted therapy: an emerging strategy in advanced ologic significance of EGFR and Her-2/neu in colorectal colorectal cancer[J]. Expert Opin Investig Drugs, 2019. adenocarcinomas[J]. Cancer J, 2006, 12(3): 229-236 28(1)29-38 2] Janusz KWA, Robert R, Maciej C, et al. Expression of [35] Bertotti A, Migliardi G, Galimi F, et al. A Molecularly HER2 in colorectal cancer does not correlate with progno- annotated platform of patient-derived xenografts(Xe- sis [J]. Dis Markers, 2010, 29(5): 207-212 nopatients")identifies HER2 as an effective therapeutic [23] Ingold Heppner B, Behrens HM, Balschun K, et al. HER2/ target in cetuximab-resistant colorectal cancer [n.Cancer neu testing in primary colorectal carcinoma [J] Br Can- Discov,201l.1(6):508-5 cer,2014,1110:1977-1984 [36] Kawuri SM, Jain N, Galimi F, et al. HER2 activating muta- [24] Song Z Deng Y. Zhuang K et al. Immunohistochemical tions are targets for colorectal cancer treatment [J]. Cancer results of HER2/neu protein expression assessed by rabbit Discov,2015,5(8):832-841 monoclonal antibodies SP3 and 4B5 in colorectal carcino- [37] Parikh A, Atreya MC, Korn PWM, et al. Prolonged masLI. Int J Clin Exp Pathol. 2014. 7(7): 4454-4460. response to HER2-directed therapy in a patient with [25] De Cuyper A. Van Den Eynde M, Machiels JP. HER2 as HER2-amplified, rapidly progressive metastatic colorectal a predictive biomarker and treatment target in colorectal er[]. J Natl Compr Canc Netw, 2017, 15(1):3-8. cancer[J]. Clin Colorect Cancer, 2020. Epub ahead of [38] Martinelli E, Troiani T, Sforza V, et al. Sequential HER2 blockade as effective therapy in chemorefractory, HER2 [26] Yonesaka K, Zejnullahu K, Okamoto L,et al. Activation of gene-amplified, RAS wild-type, metastatic colorectal ERBB2 signaling causes resistance to the EGFR-Directed r: learning from a clinical case [J]. Esmo Open. therapeutic antibody cetuximab[]. Sci Transl Med, 2011 018,3(1):e000299 [39] Siena S. Sartore-Bianchi A. Trusolino L et al. Abstract [27 Hermann B. Matthias K. Christian PP et al. Colorectal CTo05 Final results of the heracles trial in heR2 am ancer[J. Lance,2014,38309927)1490-1502 plified colorectal cancer. Anti-HER2 treatment in HER2+ [28] Mohan S Heitzer E. Ulz P. et al. Changes in colorectal mCRC[]. Cancer Res, 2017. 77(suppl 13):CT005 carcinoma genomes under anti-EGFR therapy ide [40] Sandhu J, Wang C, Fakih M. Clinical response to T-DMI by whole-genome plasma DNA sequencing[J] in HER2-amplified, KRAS-mutated metastatic colorectal Genet,2014.103):el004271 cancer[J]. J Natl Compr Canc Netw. 2020. 18(2): 116-119 [29] Raghav KPS, Overman MJ, Yu R, et al. HER2 amplifica- [41] Benson AB, Venook AP, Cederquist L, et al.Colorectal tion as a negative predictive biomarker for anti-epidermal cancer,version 2. 2018. NCCN clinical practice guidelines wth factor receptor antibody therapy in metastatic col- oncology [Jl. J Natl Compr Canc Netw, 2017, 15(3): ectal cancer [J]. J Clin Oncol, 2016, 34(suppl 15): 3517 370-398 [30] Piccart-Gebhart M, Procter M, Leyland-Jones B, et al. Tras- [42] Moulder-Thompson S. Borges VF, Baetz TD,et al.Phase tuzumab after adjuvant chemotherapy in HER2-positive I study of ONT-380, a HER2 inhibitor, in patients with breast cancer [J]. N Engl J Med. 2005,353(16: 1659-1672 HER2+ advanced solid tumors, with an expansion cohort [31] Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus in HER2+ metastatic breast cancer(MBC)[J]. Clin Can adjuvant chemotherapy for operable HER2-positive breast cer res,2017,23(14):3529-3536·200· Journal of Practical Oncology Vol.35 No.3 2020 www.syzlzz.com [18] Kapitanović S, Radosević S, Kapitanović M, et al. The ex￾pression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer[J], Gastroenter￾ology, 1997, 112(4): 1103-1113. [19] Osako T, Miyahara M, Uchino S, et al. Immunohistochem￾ical study of c-erbB-2 protein in colorectal cancer and the correlation with patient survival[J]. Oncology, 1998, 55(6): 548-555. [20] Laurent-Puig P, Balogoun R, Cayre A, et al. ERBB2 al￾terations a new prognostic biomarker in stage Ⅲ colon cancer from a FOLFOX based adjuvant trial (PETACC8) [J]. Ann Oncol, 2016, 27(suppl 6):149-206. [21] Kountourakis P, Pavlakis K, Psyrri A, et al. Clinicopath￾ologic significance of EGFR and Her-2/neu in colorectal adenocarcinomas[J]. Cancer J, 2006, 12(3): 229-236. [22] Janusz KWA, Robert R, Maciej C, et al. Expression of HER2 in colorectal cancer does not correlate with progno￾sis[J]. Dis Markers, 2010, 29(5): 207-212. [23] Ingold Heppner B, Behrens HM, Balschun K, et al. HER2/ neu testing in primary colorectal carcinoma[J]. Br J Can￾cer, 2014, 111(10): 1977-1984. [24] Song Z, Deng Y, Zhuang K, et al. Immunohistochemical results of HER2/neu protein expression assessed by rabbit monoclonal antibodies SP3 and 4B5 in colorectal carcino￾mas[J]. Int J Clin Exp Pathol, 2014, 7(7): 4454-4460. [25] De Cuyper A, Van Den Eynde M, Machiels JP. HER2 as a predictive biomarker and treatment target in colorectal cancer[J]. Clin Colorect Cancer, 2020, Epub ahead of print. [26] Yonesaka K, Zejnullahu K, Okamoto I, et al. Activation of ERBB2 signaling causes resistance to the EGFR-Directed therapeutic antibody cetuximab[J]. Sci Transl Med, 2011, 3(99): 99ra86. [27] Hermann B, Matthias K, Christian PP, et al. Colorectal cancer[J]. Lancet, 2014, 383(9927):1490-1502. [28] Mohan S, Heitzer E, Ulz P, et al. Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing[J]. PLoS Genet, 2014, 10(3): e1004271. [29] Raghav KPS, Overman MJ, Yu R, et al. HER2 amplifica￾tion as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic col￾orectal cancer[J]. J Clin Oncol, 2016, 34(suppl 15): 3517. [30] Piccart-Gebhart M, Procter M, Leyland-Jones B, et al. Tras￾tuzumab after adjuvant chemotherapy in HER2-positive breast cancer[J]. N Engl J Med, 2005,353(16):1659-1672. [31] Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer[J]. N Engl J Med, 2005, 353(16): 1673-1684. [32] Clark J, Niedzwiecki D, Hollis D, et al. Phase-Ⅱ trial of 5-fluororuacil (5-FU), leucovorin (LV), oxaliplatin (Ox), and trastuzumab (T) for patients with metastatic colorectal cancer (CRC) refractory to initial therapy[J]. Onkologie, 2003, 26:13-46. [33] Ramanathan RK, Hwang JJ, Zamboni WC, et al. Low overexpression of HER-2/neu in advanced colorectal can￾cer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase Ⅱ trial[J]. Cancer Invest, 2004, 22(6): 858-865. [34] La Salvia A, Lopez-Gomez V, Garcia-Carbonero R. HER2-targeted therapy: an emerging strategy in advanced colorectal cancer[J]. Expert Opin Investig Drugs, 2019, 28(1): 29-38. [35] Bertotti A, Migliardi G, Galimi F, et al. A Molecularly annotated platform of patient-derived xenografts ("Xe￾nopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer[J]. Cancer Discov, 2011, 1(6): 508-523. [36] Kavuri SM, Jain N, Galimi F, et al. HER2 activating muta￾tions are targets for colorectal cancer treatment[J]. Cancer Discov, 2015, 5(8): 832-841. [37] Parikh A , Atreya MC , Korn PWM , et al.Prolonged response to HER2-directed therapy in a patient with HER2-amplified, rapidly progressive metastatic colorectal cancer[J]. J Natl Compr Canc Netw, 2017, 15(1):3-8. [38] Martinelli E, Troiani T, Sforza V, et al. Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case[J]. Esmo Open, 2018, 3(1): e000299. [39] Siena S, Sartore-Bianchi A, Trusolino L et al. Abstract CT005: Final results of the HERACLES trial in HER2 am￾plified colorectal cancer. Anti-HER2 treatment in HER2+ mCRC[J]. Cancer Res, 2017, 77(suppl 13): CT005. [40] Sandhu J , Wang C , Fakih M . Clinical response to T-DM1 in HER2-amplified, KRAS-mutated metastatic colorectal cancer[J]. J Natl Compr Canc Netw, 2020, 18(2):116-119. [41] Benson AB, Venook AP, Cederquist L, et al. Colorectal cancer, version 2. 2018, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2017, 15(3): 370-398. [42] Moulder-Thompson S, Borges VF, Baetz TD, et al. Phase 1 study of ONT-380, a HER2 inhibitor, in patients with HER2+ advanced solid tumors, with an expansion cohort in HER2+ metastatic breast cancer (MBC)[J]. Clin Can￾cer Res, 2017, 23(14): 3529-3536